Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CHE
stocks logo

CHE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
658.97M
+2.97%
7.067
+3.48%
666.23M
+2.98%
5.993
+6.45%
663.87M
+7.28%
5.890
+37.94%
Estimates Revision
The market is revising Downward the revenue expectations for Chemed Corporation (CHE) for FY2025, with the revenue forecasts being adjusted by -0.01% over the past three months. During the same period, the stock price has changed by -8.88%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.27%
In Past 3 Month
Stock Price
Go Down
down Image
-8.88%
In Past 3 Month
Wall Street analysts forecast CHE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CHE is 574.25 USD with a low forecast of 550.00 USD and a high forecast of 595.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast CHE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CHE is 574.25 USD with a low forecast of 550.00 USD and a high forecast of 595.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 424.300
sliders
Low
550.00
Averages
574.25
High
595.00
Current: 424.300
sliders
Low
550.00
Averages
574.25
High
595.00
RBC Capital
Outperform -> NULL
downgrade
$589 -> $572
2025-11-10
Reason
RBC Capital
Price Target
$589 -> $572
2025-11-10
downgrade
Outperform -> NULL
Reason
RBC Capital lowered the firm's price target on Chemed to $572 from $589 and keeps an Outperform rating on the shares. The company reported solid Q3 results and reaffirmed full-year guidance, the analyst tells investors in a research note. While adjusted EBITDA in both VITAS and Roto-Rooter was slightly below Street consensus, the print was in line with the management's expectations and serves as reaffirmation of its confidence in navigating challenges, RBC added.
BofA
analyst
Buy
downgrade
$610 -> $595
2025-09-10
Reason
BofA
analyst
Price Target
$610 -> $595
2025-09-10
downgrade
Buy
Reason
BofA lowered the firm's price target on Chemed to $595 from $610 and keeps a Buy rating on the shares. While hospital fundamentals should remain solid in the second half, the firm is concerned that the policy and reimbursement environment will be more negative compared to recent years, says the analyst, who prefers post-acute over hospitals as the least exposed to the upcoming cuts given this backdrop. The firm is updating estimates and price targets for several companies in its health care facilities coverage.
Jefferies
Hold
to
Buy
upgrade
$490 -> $550
2025-09-02
Reason
Jefferies
Price Target
$490 -> $550
2025-09-02
upgrade
Hold
to
Buy
Reason
Jefferies upgraded Chemed to Buy from Hold with a price target of $550, up from $490. The company's fiscal 2026 reimbursement, particularly in Florida, came in more favorable than expected, the analyst tells investors in a research note. The firm believes this positions Chemed for 2026 EBITDA at the high end of the current Street range. Better than expected reimbursement and "aggressive" share buybacks should drive the stock's multiple higher in the near-term, contends Jefferies.
Jefferies
Hold
initiated
$500
2025-07-25
Reason
Jefferies
Price Target
$500
2025-07-25
initiated
Hold
Reason
Jefferies initiated coverage of Chemed with a Hold rating and $500 price target. The firm likes the hospice space and Chemed's track record of execution and capital allocation, but says the recent issues related to the Medicare cap, particularly in Florida, will likely carry over into 2026. These will limit Chemed's ability to achieve the consensus 2026 EBITDA estimates, the analyst tells investors in a research note.
BofA
Buy
downgrade
$708 -> $650
2025-06-30
Reason
BofA
Price Target
$708 -> $650
2025-06-30
downgrade
Buy
Reason
BofA lowered the firm's price target on Chemed to $650 from $708 and keeps a Buy rating on the shares. Chemed on Friday said that the Medicare cap will be a $20M, or 4%, headwind in 2025, which is not a surprise given the Q1 disclosures, but admissions in Florida were weaker in April and May, while Roto-Rooter residential was worse than expected, the analyst tells investors in a research note. While the stock will be pressured on the worse 2025, BofA likes the longer-term fundamentals for both Vitas and Roto.
RBC Capital
Ben Hendrix
Outperform
downgrade
$674 -> $640
2025-06-30
Reason
RBC Capital
Ben Hendrix
Price Target
$674 -> $640
2025-06-30
downgrade
Outperform
Reason
RBC Capital analyst Ben Hendrix lowered the firm's price target on Chemed to $640 from $674 and keeps an Outperform rating on the shares. The firm is disappointed to see Medicare cap limitations weigh on the 2025 outlook, though it is also encouraged by VITAS' new CON, which should help the company maintain strong positioning in an increasingly competitive FL market, the analyst tells investors in a research note. RBC adds that headwinds at Roto-Rooter continue with an unanticipated decline in residential volume, which more than offset improving commercial trends.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Chemed Corp (CHE.N) is 16.93, compared to its 5-year average forward P/E of 24.03. For a more detailed relative valuation and DCF analysis to assess Chemed Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Undervalued
5Y Average PE
24.03
Current PE
16.93
Overvalued PE
26.42
Undervalued PE
21.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
16.23
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
17.70
Undervalued EV/EBITDA
14.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.34
Current PS
0.00
Overvalued PS
3.68
Undervalued PS
2.99
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 158.47% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CHE News & Events

Events Timeline

(ET)
2025-10-28
16:21:08
Chemed reaffirms FY25 EPS forecast of $22.00-$22.30, with consensus at $22.15
select
2025-10-28
16:19:48
Chemed announces Q3 adjusted EPS of $5.27, falling short of consensus estimate of $5.36
select
2025-08-01 (ET)
2025-08-01
13:06:29
Chemed board declares increased quarterly dividend of 60c per share
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
01:21 AMGlobenewswire
Chemed Corporation to Present at BofA Securities 2025 Virtual Home Care Conference on December 9
  • Conference Announcement: Chemed Corporation will present at the BofA Securities 2025 Virtual Home Care Conference on December 9, 2025, at 1:20 PM (ET), showcasing its latest developments in the home care sector.
  • Live Webcast: The presentation will be webcast live on the Chemed website, with a replay available within 24 hours and accessible for 90 days, ensuring broad investor engagement and information dissemination.
  • Company Background: Headquartered in Cincinnati, Ohio, Chemed Corporation operates two wholly owned subsidiaries, VITAS Healthcare, the largest provider of end-of-life hospice care in the U.S., and Roto-Rooter, the leading provider of plumbing and drain cleaning services.
  • Forward-Looking Statements: The company cautions that statements in the press release may relate to future events or performance, and investors should be aware of the inherent risks that actual results may differ materially from such forward-looking statements.
[object Object]
Preview
8.0
11-19Newsfilter
Chemtrade Logistics Income Fund Announces Distribution for November 2025

  • Distribution Announcement: Chemtrade Logistics Income Fund has declared a cash distribution of $0.0575 per unit for November 2025, payable on December 31, 2025.

  • Record Date: Unitholders must be on record by the close of business on November 28, 2025, to receive the distribution.

  • Tax Implications: Non-resident unit holders in Canada will be subject to withholding taxes on any income distributions from the Fund.

  • Contact Information: For further inquiries, investors can reach out to Endri Leno, Vice President of Investor Relations, via email.

[object Object]
Preview
9.5
11-12Newsfilter
Chemtrade Logistics Income Fund Reports All-Time High Quarterly Adjusted EBITDA for Q3 2025; Raises Full-Year 2025 Guidance to Over $503 Million in Adjusted EBITDA

  • Financial Performance: Chemtrade Logistics reported a revenue of $532.8 million for Q3 2025, marking a 12.4% increase year-over-year, with Adjusted EBITDA reaching a record $151.2 million, up 10.2% from the previous year.

  • Net Earnings and Cash Flow: Despite a decrease in net earnings to $42.4 million (down 29.5% year-over-year), cash flows from operating activities increased by 8.5% to $155.5 million, contributing to a rise in distributable cash after maintenance capital expenditures to $77.8 million.

  • Acquisition and Growth Initiatives: Chemtrade is progressing with its acquisition of Polytec, a water treatment solutions provider, while also focusing on organic growth projects, including expansions in water treatment chemicals and ultrapure acid production.

  • Future Outlook: The company anticipates a record Adjusted EBITDA for 2025, exceeding $502.6 million, driven by favorable market conditions and operational excellence, despite ongoing global trade tensions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Chemed Corp (CHE) stock price today?

The current price of CHE is 424.3 USD — it has decreased -1.52 % in the last trading day.

arrow icon

What is Chemed Corp (CHE)'s business?

Chemed Corporation is engaged in purchasing, operating, and divesting subsidiaries in diverse business activities. The Company's segment includes VITAS and the Roto-Rooter. The VITAS segment provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. It provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. The Roto-Rooter segment provides plumbing, drain cleaning, excavation, water restoration and other related services to residential and commercial customers. The Roto-Rooter services are provided through a network of Company-owned branches, independent contractors and franchisees. The Company's water restoration services involve the remediation of water and humidity after a flood and are provided to both commercial and residential customers.

arrow icon

What is the price predicton of CHE Stock?

Wall Street analysts forecast CHE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CHE is 574.25 USD with a low forecast of 550.00 USD and a high forecast of 595.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Chemed Corp (CHE)'s revenue for the last quarter?

Chemed Corp revenue for the last quarter amounts to 624.90M USD, increased 3.09 % YoY.

arrow icon

What is Chemed Corp (CHE)'s earnings per share (EPS) for the last quarter?

Chemed Corp. EPS for the last quarter amounts to 4.46 USD, decreased -10.80 % YoY.

arrow icon

What changes have occurred in the market's expectations for Chemed Corp (CHE)'s fundamentals?

The market is revising Downward the revenue expectations for Chemed Corporation (CHE) for FY2025, with the revenue forecasts being adjusted by -0.01% over the past three months. During the same period, the stock price has changed by -8.88%.
arrow icon

How many employees does Chemed Corp (CHE). have?

Chemed Corp (CHE) has 15695 emplpoyees as of December 05 2025.

arrow icon

What is Chemed Corp (CHE) market cap?

Today CHE has the market capitalization of 6.01B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free